Pathology CME

Credits: 1.50 CME / MOC / CC
Medical Learning Institute, Inc.
Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation
Suresh S. Ramalingam, MD, FACP, FASCO
May 11, 2021
Credits: 1.00 CME / MOC / CC
Medical Learning Institute, Inc.
Precision Decisions in Genomic Testing and Targeted Treatment of NSCLC
Paul A. VanderLaan, MD, PhD
April 13, 2021
Credits: 1.00 CME / MOC / CC
Medical Learning Institute, Inc.
HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors: Implications for Pathology and Oncology Practice
Kurt A. Schalper, MD, PhD
April 6, 2021
Credits: 1.00 CME / MOC / CC
Medical Learning Institute, Inc.
New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape
Maria Arcila, MD
January 26, 2021
Credits: 1.00 CME / MOC / CC
Medical Learning Institute, Inc.
Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists
Kurt Schalper, MD, PhD
October 16, 2020
Credits: 1.00 CME / MOC / CC
Medical Learning Institute, Inc.
The Pathology–Oncology Partnership in AML: Identifying and Treating the Diversity of Disease Subtypes
Naval Daver, MD / Joseph D. Khoury, MD, FCAP
October 15, 2020
Credits: 1.00 CME / MOC / CC
Medical Learning Institute, Inc.
Modern Diagnostics and Targeted Therapy for TRK Fusion Cancers: Pathology-Oncologist Collaboration in the Era of Precision Medicine
George D. Demetri, MD
July 31, 2020
Medical Learning Institute, Inc.
Increasing Importance of HER2 and HER3 Testing in the Context of an Expanding Targeted Therapies Landscape for Breast, Gastrointestinal, Lung, and Other Cancers: Latest Updates and Practical Guidance for Pathologists
Farnaz Dadmanesh, MD
April 6, 2020

Education Collections